Picture of DURECT logo

DRRX — DURECT News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Durect Corp Expected To Post A Loss Of 4 Cents A Share: Earnings Preview

* DURECT Corp  DRRX.OQ   DRRX.O  is expected to show a fall in
quarterly revenue when it reports results on July 29. 
* The Cupertino, California-based company is expected to report 
 a 85.9% decrease in revenue to $3.65 million from $25.84
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for DURECT Corp is for a
loss of 4 cents per share. For the same quarter last year, the
company reported earnings of 7 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by about 2.2%
in the last three months. ​
* Wall Street's median 12-month price target for DURECT Corp is
$7​, about 80.6% above​ its last closing price of $1.36. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.04       -0.04      -0.05     Missed  -13.6
 Dec. 31 2020  0.02        -0.03      -0.04     Missed  -26.3
 Sep. 30 2020  -0.04       -0.04      -0.05     Missed  -15.4​
 Jun. 30 2020  0.02        0.02       0.07      Beat    366.7
 Mar.          -0.03​      -0.04      -0.05     Missed  -38.9​
 31​ 2020​                                              
 Dec. 31 2019  0.00        -0.02      -0.02     Met     -25​
 Sep. 30 2019  0.03        0.02       -0.01     Missed  -150
 Jun. 30 2019  -0.04       -0.04      -0.04     Met     11.1
 This summary was machine generated July 27 at 22:34 GMT.  All
figures in US dollars unless otherwise stated

Recent news on DURECT

See all news